

Orchestrating Ca²⁺ influx through Ca_v1.2 and Ca_v3.x channels in human cerebral arteries

Daniel M. Collier, David C. Hill-Eubanks, and Mark T. Nelson

Department of Pharmacology, University of Vermont, Burlington, VT 05405

Vascular tone, and thus blood flow to a tissue bed, is regulated by neuronal-, endothelial-, and smooth muscle-dependent mechanisms. The smooth muscle-dependent component, reflecting the increase in arterial tone in response to increasing pressure (the myogenic response), has been appreciated for over 100 yr (Bayliss, 1902). This myogenic response is an important component of cerebral blood flow (CBF) autoregulation, in which cerebral arteries constrict to an increase in blood pressure so as to maintain constant CBF. Elevation of intraluminal pressure leads to smooth muscle membrane depolarization and ultimately activation of voltage-dependent Ca²⁺ (Ca_v) channels. This results in the influx of Ca²⁺ into the cytosol and the initiation of smooth muscle contraction. Dihydropyridine-sensitive, L-type Ca_v channels, in particular Ca_v1.2, figure prominently in the development of myogenic tone (Rubart et al., 1996; Knot and Nelson, 1998). Recently, a more nuanced picture has emerged, with T-type channels also playing a role in Ca²⁺ delivery for constriction over negative membrane potentials (Ca_v3.1/Ca_v3.3) or in privileged communication to large-conductance, Ca²⁺-sensitive K⁺ (BK) channels to oppose depolarization and constriction (Ca_v3.2; Harraz et al., 2014). Thus, the triumvirate of Ca_v1.2, Ca_v3.2, and Ca_v3.3 (or Ca_v3.1 in rats) channels appears to orchestrate the myogenic response to increases in intravascular pressure. However, the majority of these studies have used cerebral arteries from rodents. The specific expression, function, and contribution of Ca_v channels to arterial tone in human arterial smooth muscle are not known.

Harraz et al. (2015) test a key assumption in the field: that Ca_v function in rodent arterial smooth muscle of the cerebral circulation is a valid model for assessing Ca_v function in human arterial smooth muscle in the brain. In this comprehensive study using human cerebral arteries, the authors determine the composition of Ca_v isoforms, their functional properties, and their contribution to myogenic tone.

Ca_v channel pharmacology and significance in human disease

Ca_v channels are five-subunit complexes composed of a pore-forming α1 subunit and accessory α2, β, δ, and

γ subunits. Ca_v channels are segregated into different types depending on Ca²⁺ current properties of the α1 subunit, exemplified by L-type (“long lasting”) Ca_v1.1, 1.2, 1.3, and 1.4 channels and T-type (“transient”) Ca_v3.1, 3.2, and 3.3 channels. L- and T-type Ca_v channels exhibit different activation and inactivation properties, with L-type channels displaying an activation curve shifted to more positive voltages (Perez-Reyes, 2003; Catterall, 2011). A rich pharmacology is available for manipulating L-type channels, including several therapeutic drugs such as dihydropyridines (e.g., nifedipine) that are capable of selectively inhibiting the channel. Comparatively speaking, pharmacological options for manipulating T-type channels are very limited. One drug, mibefradil, was initially touted as a selective T-type channel antagonist and made a brief appearance on the market before potentially serious drug interactions made it clear that the drug was not selective (Bezprozvanny and Tsien, 1995; Stolberg, 1998).

Ca_v channels are involved in various human diseases. L-type Ca_v1 channels have been implicated in Timothy syndrome, cardiac arrhythmias, and autism spectrum disorders, and T-type Ca_v3 channels are involved in absence seizures, an inherited epileptic syndrome. Overexpression of Ca_v channels has also been shown to play a role in cancer progression and peripheral diabetic neuropathy (Nelson et al., 2006; Catterall, 2011; Dziegielewska et al., 2014).

Ca_v function in human cerebral vasculature

Much of what is known about the structure, function, and expression of Ca_v channels comes from experiments in rodent models, begging the question: do human cerebral arteries behave similarly to cerebral arteries from rodents? Making judicious use of the meager pharmacological tools available (NNC 55-0396 indiscriminately blocks all T-type channel subtypes and is nonselective at higher concentrations, whereas nickel at 50 μM appears to be selective for Ca_v3.2 channels [Harraz et al., 2014]), Harraz et al. (2015) set out to

Correspondence to Mark T. Nelson: mark.nelson@uvm.edu

uncover the functional role of Ca_v subtypes in regulating arterial tone in human cerebral arteries. These functional analyses were complemented by molecular and biochemical techniques to determine human Ca_v expression at mRNA and protein levels. All of these experiments used surface (pial) cerebral arteries collected from patients undergoing resection surgery to remove a tumor (glioblastoma or metastasis from another site) or alleviate various forms of epilepsy or seizure.

Directly comparing channel properties in isolated smooth muscle cells (SMCs) from humans, rats, and mice, Harraz et al. (2015) found that inward Ba^{2+} current density was notably smaller in human SMCs than in rodents. However, the current–voltage relationships of normalized maximal currents were similar, suggesting a common molecular basis. Similar leftward shifts in activation and inactivation curves were seen before and after application of nifedipine, indicative of the presence of both L- and T-type currents in human, mouse, and rat SMCs. Moreover, myogenic responses of human cerebral arteries were similar to previously published findings on rodents (Knot and Nelson, 1998).

Based on the relationship between pressure and diameter in the presence of nifedipine (L-type inhibition) and NNC 55-0396 (T-type inhibition) and the absence of external Ca^{2+} , to minimize Ca^{2+} entry through all pathways, the authors concluded that L- and T-type channels contribute similarly to tone at 20 and 40 mm Hg, whereas L-type channels dominate at pressures of 60–100 mm Hg. It had been previously shown that graded elevation of intravascular pressure from 20 to 100 mm Hg causes a graded membrane potential depolarization




Figure 1. Model of the contribution of Ca_v channels to smooth muscle tone. $Ca_v1.2$ (dark blue) and $Ca_v3.3$ (purple) promote smooth muscle contraction by allowing Ca^{2+} entry. The relative contribution of each depends on intraluminal pressure (or membrane potential). $Ca_v1.2$ is the major contributor between -50 and -35 mV (higher pressure, >40 mm Hg) whereas $Ca_v3.3$ is the major contributor between -60 and -50 mV (lower pressure, 20–40 mm Hg). $Ca_v3.2$ (light blue) opposes contraction through activation of Ca^{2+} sparks/RyRs through BK channel–dependent membrane hyperpolarization. Model is based on the data of Harraz et al. (2015).

of rat pial arteries from about -60 to -36 mV (Knot and Nelson, 1998), with 40 mm Hg corresponding to about -53 mV. Assuming that the membrane potential of human pial arteries is similar to that of rat arteries, these data collectively suggest that T-type channels have a significant role over a membrane potential range of -60 to -50 mV, a conclusion consistent with results of the authors' previous study using rodent cerebral arteries (Harraz et al., 2014). One notable difference between the human and rodent findings was that human cerebral arteries use $Ca_v3.3$, and not $Ca_v3.1$, to accomplish this task. Paradoxically, however, $Ca_v3.2$ exerted opposing effects. Harraz et al. (2015) provide evidence that $Ca_v3.2$ typically promotes vasodilation through a Ca^{2+} spark, BK-dependent mechanism (Fig. 1; Harraz et al., 2014). This suggests that the consequences of T-type channel suppression may vary depending on the relative contribution of $Ca_v3.3$ and $Ca_v3.2$ channels.

Intravital microscopy and *in vivo* measurements of vessel diameter and red blood cell velocity can be readily applied to animal models but are not generally suited to human experimentation. To circumvent this limitation, Harraz et al. (2015) generated a computer model to mimic a native cerebral arterial surface network based on the architecture, pressurized vessel myography, and electrophysiological data obtained from human tissue. The resulting model provides a starting point for predicting changes in blood flow that will become increasingly useful as more is understood about the degree to which $Ca_v3.3$ and $Ca_v3.2$ promote or inhibit arterial tone depending on the relative subtype dominance in a given tissue bed. As this information becomes available for various diseases, it may be possible to use the model to discern the appropriate balance of L-type- and T-type-specific drugs necessary to “tune” Ca_v activity in a given tissue bed.

Paving the way for future studies on human cerebral vasculature

The work of Harraz et al. (2015) accomplishes two important tasks. First, and foremost, it is an impressively detailed study covering a broad range of approaches that include molecular analyses, tissue function, native channel function, and computer modeling in the most difficult of experimental systems: humans. Second, the caveats of the study, mainly its limited, heterogeneous subject population, highlight just how powerful rodent models can be for understanding human disease. By providing the ability to control age, genetic and environmental variability, and sample size, rodent models provide an invaluable tool for testing hypotheses in living systems that cannot otherwise be tested *in vitro* or *in silico*. It is notable how much of the data are in agreement with previously reported data from rodent models. In particular, the work of Harraz et al. (2015) in human tissue provides important confirmation of their previous findings on divergent roles of $Ca_v3.1$ and $Ca_v3.2$ in rat

cerebral arteries (Harraz et al., 2014), which may have therapeutic implications.

Out of necessity, most investigations on Ca_V channels have used Ba^{2+} as a charge carrier to increase current amplitude and have used conventional voltage-clamp protocols to examine activation and inactivation properties. In typical experiments on myogenic tone, pressure is stepped to different levels and held for minutes. Thus, exploring Ca_V properties under conditions similar to these would require measurement of steady-state currents, which, because of slow inactivation, are likely to be different from those inferred from short conditioning voltage pulses (Rubart et al., 1996). Ca^{2+} -dependent inactivation, which is absent in experiments with Ba^{2+} , provides an additional complicating factor. To better simulate physiology, it would therefore be important to measure steady-state Ca^{2+} currents through $\text{Ca}_V1.2$, $\text{Ca}_V3.2$, and $\text{Ca}_V3.3$ channels over the membrane potential range (-60 to -36 mV) encompassed by intraluminal pressures of 20–100 mm Hg. Moreover, in vivo membrane potential likely continuously changes in response to the change in intraluminal pressure with each heartbeat. In mice, mean arterial pressure cycles every ~ 100 ms, whereas human mean arterial pressure cycles every $\sim 1,000$ ms. Therefore, it is tempting to speculate that differences in the kinetics of $\text{Ca}_V3.3$ (human) and $\text{Ca}_V3.1$ (rodent) are responsible for accommodating differences in pulse-pressure profiles in humans and rodents.

The proposed orchestration of Ca^{2+} influx into cerebral artery SMCs by $\text{Ca}_V1.2$, $\text{Ca}_V3.3$, and $\text{Ca}_V3.2$ channels, which supply Ca^{2+} over different pressure/membrane potential ranges ($\text{Ca}_V1.2$ and $\text{Ca}_V3.3$) and preferentially activate BK channels ($\text{Ca}_V3.2$), suggests a marvel of subspecialization (Fig. 1). Understanding how $\text{Ca}_V3.2$ can preferentially communicate with BK channels will be critical to understanding their regulation of cerebral artery tone. Based on the ability of Ni^{2+} to inhibit Ca^{2+} spark-activated BK currents, it would appear that $\text{Ca}_V3.2$ channels reside in a privileged Ca^{2+} communication complex with ryanodine receptors (RyRs) in the sarcoplasmic reticulum and nearby surface membrane BK channels (Harraz et al., 2014), an arrangement reminiscent of that described for TRPV4 channels–RyRs–BK channels in rat cerebral arteries (Earley et al., 2005). This inferred “nanostructure” cries out for further exploration using super-resolution microscopy. The observed opposing roles of $\text{Ca}_V3.2$ and $\text{Ca}_V3.3$ in human cerebral arteries dictates that therapeutic interventions will ultimately require Ca_V3 subtype-specific modulators, elevating an already challenging pharmacology (Fig. 1).

Studies on human cerebral arteries are constrained by several limitations, including small sample size, heterogeneous populations, and difficulty of obtaining material from healthy individuals. Champions of translational research will laud the basic science rigor with which

Harraz et al. (2015) directly approach human physiology. Those with a more basic science bent may bemoan the fact that the tissues were obtained from a small sample of subjects with diseases that may have been the result of perturbations of Ca_V function or expression. Ultimately, the importance of performing basic research on human tissue takes precedence over such concerns, legitimate though they may be. In the case of the study by Harraz et al. (2015), the novelty of the findings presented is certain to pave the way for future studies.

This work was supported by grants from the National Institutes of Health (P01-HL-095488, R01-HL-121706, and R37-DK-053832), Totman Medical Research Trust, and the Fondation Leducq.

The authors declare no competing financial interests.

Elizabeth M. Adler served as editor.

REFERENCES

- Bayliss, W.M. 1902. On the local reactions of the arterial wall to changes of internal pressure. *J. Physiol.* 28:220–231. <http://dx.doi.org/10.1113/jphysiol.1902.sp000911>
- Bezprozvanny, I., and R.W. Tsien. 1995. Voltage-dependent blockade of diverse types of voltage-gated Ca^{2+} channels expressed in *Xenopus* oocytes by the Ca^{2+} channel antagonist mibefradil (Ro 40-5967). *Mol. Pharmacol.* 48:540–549.
- Catterall, W.A. 2011. Voltage-gated calcium channels. *Cold Spring Harb. Perspect. Biol.* 3:a003947. <http://dx.doi.org/10.1101/cshperspect.a003947>
- Dziegielewska, B., L.S. Gray, and J. Dziegielewski. 2014. T-type calcium channels blockers as new tools in cancer therapies. *Pflugers Arch.* 466:801–810. <http://dx.doi.org/10.1007/s00424-014-1444-z>
- Earley, S., T.J. Heppner, M.T. Nelson, and J.E. Brayden. 2005. TRPV4 forms a novel Ca^{2+} signaling complex with ryanodine receptors and BK_{Ca} channels. *Circ. Res.* 97:1270–1279. <http://dx.doi.org/10.1161/01.RES.0000194321.60300.d6>
- Harraz, O.F., R.R. Abd El-Rahman, K. Bigdely-Shamloo, S.M. Wilson, S.E. Brett, M. Romero, A.L. Gonzales, S. Earley, E.J. Vigmond, A. Nygren, et al. 2014. $\text{Ca}_V3.2$ channels and the induction of negative feedback in cerebral arteries. *Circ. Res.* 115:650–661. <http://dx.doi.org/10.1161/CIRCRESAHA.114.304056>
- Harraz, O.F., F. Visser, S.E. Brett, D. Goldman, A. Zechariah, A.M. Hashad, B.K. Menon, T. Watson, Y. Starreveld, and D.G. Welsh. 2015. $\text{Ca}_V1.2/\text{Ca}_V3.x$ channels mediate divergent vasomotor responses in human cerebral arteries. *J. Gen. Physiol.* 145:405–418. <http://dx.doi.org/10.1085/jgp.201511361>
- Knot, H.J., and M.T. Nelson. 1998. Regulation of arterial diameter and wall $[\text{Ca}^{2+}]$ in cerebral arteries of rat by membrane potential and intravascular pressure. *J. Physiol.* 508:199–209. <http://dx.doi.org/10.1111/j.1469-7793.1998.199br.x>
- Nelson, M.T., S.M. Todorovic, and E. Perez-Reyes. 2006. The role of T-type calcium channels in epilepsy and pain. *Curr. Pharm. Des.* 12:2189–2197. <http://dx.doi.org/10.2174/13816120677585184>
- Perez-Reyes, E. 2003. Molecular physiology of low-voltage-activated T-type calcium channels. *Physiol. Rev.* 83:117–161. <http://dx.doi.org/10.1152/physrev.00018.2002>
- Rubart, M., J.B. Patlak, and M.T. Nelson. 1996. Ca^{2+} currents in cerebral artery smooth muscle cells of rat at physiological Ca^{2+} concentrations. *J. Gen. Physiol.* 107:459–472. <http://dx.doi.org/10.1085/jgp.107.4.459>
- Stolberg, S.G. 1998. “Heart Drug Withdrawn As Evidence Shows It Could Be Lethal.” *The New York Times*, June 9, 1998.